M M Saiyed1, P S Ong1, L Chew1. 1. Department of Pharmacy, Faculty of Science, National University Singapore, Singapore.
Abstract
WHAT IS KNOWN AND OBJECTIVE: The off-label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off-label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decision-making, increased out-of-pocket costs for patients and ethical concerns around the lack of informed consent. Currently, data pertaining to the global prevalence of off-label use in cancer therapy are lacking. The aim of this review was to provide an overview of off-label drug use prevalence in oncology. METHODS: A systematic literature search was performed in PubMed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from 1975 to 2016. Studies assessing the prevalence of off-label use of anticancer drugs were included. DATA SYNTHESIS: Of the 199 eligible papers retrieved, 23 studies were included in this systematic literature review. Off-label drug use in inpatients ranged from 18% to 41%. Among adult patients with cancer, 13%-71% received a minimum of one off-label chemotherapy. The main reasons for off-label drug use were 'drug unapproved for specific tumour' and 'modified drug applications'. Among adults, metastatic cancers and palliative care patients received the most off-label drugs. The off-label drug use unsupported by standard treatment guidelines or drug compendia was in the range of 7%-31%. CONCLUSION: Off-label drug use in cancer therapy is commonly practised but outcomes could vary significantly. Hence, greater scrutiny and robust clinical guidance is needed to establish the favourable benefit-risk ratio for patients at the time of prescribing at each level of oncology care to facilitate rational off-label prescribing.
WHAT IS KNOWN AND OBJECTIVE: The off-label use of medicines is widespread in several diseases. This type of prescribing practice is particularly more acute in oncology. However, the suitability of anticancer medications for off-label use remains an issue of controversy, due to uncertainty around the clinical benefits and potential toxicities, limited evidence to support clinical decision-making, increased out-of-pocket costs for patients and ethical concerns around the lack of informed consent. Currently, data pertaining to the global prevalence of off-label use in cancer therapy are lacking. The aim of this review was to provide an overview of off-label drug use prevalence in oncology. METHODS: A systematic literature search was performed in PubMed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from 1975 to 2016. Studies assessing the prevalence of off-label use of anticancer drugs were included. DATA SYNTHESIS: Of the 199 eligible papers retrieved, 23 studies were included in this systematic literature review. Off-label drug use in inpatients ranged from 18% to 41%. Among adult patients with cancer, 13%-71% received a minimum of one off-label chemotherapy. The main reasons for off-label drug use were 'drug unapproved for specific tumour' and 'modified drug applications'. Among adults, metastatic cancers and palliative care patients received the most off-label drugs. The off-label drug use unsupported by standard treatment guidelines or drug compendia was in the range of 7%-31%. CONCLUSION: Off-label drug use in cancer therapy is commonly practised but outcomes could vary significantly. Hence, greater scrutiny and robust clinical guidance is needed to establish the favourable benefit-risk ratio for patients at the time of prescribing at each level of oncology care to facilitate rational off-label prescribing.
Authors: Danielle Potter; Raven Brothers; Andrej Kolacevski; Jacob E Koskimaki; Amy McNutt; Robert S Miller; Jatin Nagda; Anil Nair; Wendy S Rubinstein; Andrew K Stewart; Iris J Trieb; George A Komatsoulis Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Kelsey S Lau-Min; Yimei Li; Jennifer R Eads; Xiaoliang Wang; Neal J Meropol; Ronac Mamtani; Kelly D Getz Journal: Cancer Date: 2021-03-17 Impact factor: 6.921
Authors: Jean-François Laes; Philippe Aftimos; Philippe Barthelemy; Joaquim Bellmunt; Guy Berchem; Carlos Camps; Ramón de Las Peñas; Ana Finzel; Jesús García-Foncillas; Petteri Hervonen; Ibrahim Wahid; Timo Joensuu; Louis Kathan; Anthony Kong; James Mackay; Christos Mikropoulos; Kefah Mokbel; Jean-Loup Mouysset; Sergey Odarchenko; Timothy J Perren; Rika Pienaar; Carlos Regonesi; Shadi Salem Alkhayyat; Abdul Rahman El Kinge; Omalkhair Abulkhair; Khaled Morsi Galal; Hady Ghanem; Fadi El Karak; Angel Garcia; Gregori Ghitti; Helen Sadik Journal: Oncotarget Date: 2018-04-17